Avanos Medical, Inc. (NYSE:AVNS) Short Interest Down 13.3% in February

Avanos Medical, Inc. (NYSE:AVNS) was the recipient of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 2,954,825 shares, a drop of 13.3% from the January 29th total of 3,409,612 shares. Currently, 6.5% of the company’s stock are sold short. Based on an average daily trading volume, of 586,195 shares, the short-interest ratio is currently 5.0 days. Based on an average daily trading volume, of 586,195 shares, the short-interest ratio is currently 5.0 days. Currently, 6.5% of the company’s stock are sold short.

Institutional Trading of Avanos Medical

Institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its stake in Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after buying an additional 1,423 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Avanos Medical by 49.7% in the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after acquiring an additional 894 shares during the period. Russell Investments Group Ltd. grew its position in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares in the last quarter. Wexford Capital LP purchased a new position in shares of Avanos Medical in the third quarter valued at $70,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Avanos Medical by 433.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after purchasing an additional 5,083 shares during the period. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Avanos Medical Stock Down 0.8%

Shares of NYSE AVNS opened at $13.77 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.15 and a quick ratio of 1.26. The stock has a market capitalization of $640.31 million, a PE ratio of -8.72 and a beta of 1.07. Avanos Medical has a one year low of $9.30 and a one year high of $15.68. The business’s fifty day moving average price is $13.25 and its 200-day moving average price is $12.18.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. The business had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm’s quarterly revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, equities research analysts anticipate that Avanos Medical will post 1.32 EPS for the current year.

Analyst Ratings Changes

AVNS has been the subject of several recent analyst reports. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Wall Street Zen downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.